English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The improvement in plasma cell myeloma (PCM) treatment and much longer overall survival of the patients led to the observation of long-term complications of the therapy. These include secondary malignancies, such as myelodysplastic syndromes (MDS) and acute myeloid leukemia. Definitely less common is the co-occurrence of MDS at the point of diagnosis of PCM or MDS evolving during the observation of untreated patients with monoclonal gammapathy of undetermined significance. In the article we describe 5 patients: one with a therapy-related MDS, the co-occurrence of both diseases from the diagnosis and MDS preceding PCM for several years.

Współistnienie dyskrazji komórek plazmatycznych i zespołu mielodysplastycznego — opisy przypadków i przegląd piśmiennictwa